Kodiak Sciences shares surge 63.74% intraday after Zenkuda meets GLOW2 trial primary endpoint and company plans to expedite BLA submission.

Kodiak Sciences surged 63.74% in intraday trading, after announcing its drug Zenkuda met the primary endpoint in its GLOW2 Phase 3 study, showing 62.5% of patients achieved ≥2-step improvement in diabetic retinopathy severity compared to 3.3% in the sham group (p<0.0001) with an 85% reduction in risk of vision-threatening complications, prompting plans to accelerate its Biologics License Application submission.